CORRIGENDUM

Monitoring and Management of Fibrodysplasia Ossificans Progressiva: Current Perspectives [Corrigendum]


On page 118, Treatments in Development section, 2nd paragraph, 2nd sentence “The only drug in development for FOP in this medication class is Palovarotene, a retinoic acid-gamma (RAR-γ) antagonist” should read “The only drug in development for FOP in this medication class is Palovarotene, a retinoic acid-gamma (RAR-γ) agonist”.

The authors affirm that this error does not affect the results, discussion, and conclusions of the reported study and apologize for any inconvenience caused to the readers.